TAG
#drug-discovery
Stories connected through a shared idea, actor, technology or theme.
AstraZeneca signs up to $1.5 billion AI drug-discovery deal with insitroAstraZeneca will pay $40 million upfront, with insitro eligible for up to approximately $1.46 billion in development and commercial milestones. Insitro will use its Virtual Human platform to identify causal disease biology for MASH and cardiomyopathies.→Ginkgo integrates high-content cellular imaging into its autonomous Nebula labThe system adds real-time cellular imaging and high-throughput data generation to Nebula’s robotic workflows. The resulting curated datasets are intended to train and validate AI models for drug discovery.→Danaher plans an AI-powered autonomous laboratory for antibody discoveryThe planned lab will combine technologies from Abcam, Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies and Molecular Devices. Danaher says the system is intended to accelerate affinity-reagent discovery by up to eight times and increase reagent generation as it scales.→AbbVie and Iambic partner on AI-driven small-molecule discoveryThe partnership will use Iambic’s Enchant v3 model and NeuralPLexer technology to evaluate many molecular properties and design hypotheses in parallel. Iambic will receive an upfront payment and may receive milestone payments and royalties, but the release does not disclose the financial terms or clinical outcomes of the collaboration.→Obama urges Democrats to develop a clear AI safeguards planObama said Democrats need a clear plan for addressing AI's economic and safety consequences, according to reporting based on a partial transcript of a fundraising event. He described privately controlled AI as potentially dangerous if unmanaged but potentially beneficial for applications such as drug development.→Google DeepMind launches AlphaGenome Atlas for interpreting human genetic variationThe atlas covers all 9 billion possible single-letter changes in the human genome and is backed by a petabyte-scale dataset. Google DeepMind is making an academic web portal available for exploring variant effects and disease-relevant regulatory regions.→